Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-11-LABX-0021)
Ligue Contre le Cancer
Institut National du Cancer
Centre Georges-François Leclerc
Fondation pour la Recherche Medicale
Conseil régional de Bourgogne-Franche-Comté
Received: 2 August 2019
Accepted: 24 February 2020
First Online: 3 March 2020
Ethics approval and consent to participate
: This study, supported by the Centre Georges-François Leclerc and approved by the local ethics committee, was authorised by the French Health Agency (ANSM- Agence Nationale de la Sécurité du Médicaments et des produits de santé”, n°2014-A01638-39) in May 2015, and by the French Ethical Research Committee (CPP- “Comité de Protection des Personnes”) in February 2015. The clinical trial has been registered at ExternalRef removed with the identifier NCT02662621.Participants must provide informed consent in agreement with the Declaration of Helsinki. Subjects will be informed of the objectives of the project and the risks and benefits of the explorations to be carried out. None of the tests will pose risks that could endanger the lives of participants. Confidentiality of participant data will be guaranteed at all times in agreement with the CNIL MR01 reference methodology registered for CGFL (1878714v0, 30/07/2015).
: This section is not applicable.
: The authors declare that they have no competing interests.